Melendez Dante, Razonable Raymund R
Division of Infectious Diseases and the William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN 55905, USA.
Expert Rev Clin Immunol. 2014 Sep;10(9):1213-27. doi: 10.1586/1744666X.2014.943190. Epub 2014 Jul 31.
The impact of CMV infection and disease in solid organ transplant (SOT) recipients continues despite remarkable improvements in its prevention and management with antiviral drugs. Studies that have investigated the host immune response to CMV have paved way for the development of novel immune-based assays that are anticipated to complement the current antiviral-based strategies for CMV management after transplantation. In this article, we review the emerging data on the clinical application of innovative CMV-specific T-cell assays, including their role in risk-stratification, prognostication, prevention and treatment of CMV infection and disease in SOT recipients.
尽管使用抗病毒药物预防和管理巨细胞病毒(CMV)感染已取得显著进展,但CMV感染和疾病对实体器官移植(SOT)受者的影响仍在持续。研究宿主对CMV的免疫反应为新型免疫检测方法的开发铺平了道路,这些检测方法有望补充目前基于抗病毒药物的移植后CMV管理策略。在本文中,我们综述了关于创新型CMV特异性T细胞检测临床应用的最新数据,包括它们在SOT受者CMV感染和疾病的风险分层、预后评估、预防和治疗中的作用。